-
Something wrong with this record ?
Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
PJ. Marchena, I. Tzoran, B. Brenner, M. Martín, R. Malý, A. Bura-Riviere, R. Valle, L. Hernández-Blasco, JB. López-Sáez, M. Monreal, RIETE Investigators,
Language English Country Germany
Document type Journal Article
- MeSH
- Anticoagulants therapeutic use MeSH
- Databases, Factual MeSH
- Hemorrhage drug therapy epidemiology MeSH
- Drug Interactions * MeSH
- Middle Aged MeSH
- Humans MeSH
- Psychotropic Drugs therapeutic use MeSH
- Risk MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Venous Thromboembolism drug therapy epidemiology MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Spain MeSH
BACKGROUND: The influence (if any) of the use of psychotropic drugs on outcome in patients receiving anticoagulant therapy for venous thromboembolism (VTE) has not been consistently evaluated. METHODS: We used data from the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the risk for VTE recurrences, major bleeding, or death during the course of anticoagulant therapy, according to the use of psychotropics at baseline. RESULTS: Among 49,007 patients with VTE enrolled from February 2009 to September 2019, total 5,230 (11%) were using psychotropics at baseline: antidepressants 3,273 (6.7%), antipsychotics 1,588 (3.2%), and anticholinesterases 369 (0.7%). During the course of anticoagulation, 1,259 patients developed VTE recurrences, 1,231 bled, and 3,988 died (fatal pulmonary embolism 269 and fatal bleeding 187). On multivariable analysis, patients using psychotropics at baseline had a similar risk for VTE recurrences (adjusted hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.58-1.12), a nonsignificantly higher risk for major bleeding (adjusted HR: 1.15; 95% CI: 0.97-1.35), and a higher risk for intracranial bleeding (adjusted HR: 1.83; 95% CI: 1.32-2.53) or death (adjusted HR: 1.44; 95% CI: 1.32-1.57) compared with those not using psychotropics. When separately analyzed, the highest risk for intracranial bleeding was found in patients using antidepressants (adjusted HR: 1.60; 95% CI: 1.08-2.37) or antipsychotics (adjusted HR: 2.02; 95% CI: 1.17-3.49) but not in those on anticholinesterases (adjusted HR: 1.69; 95% CI: 0.62-4.60). CONCLUSION: During the course anticoagulation for VTE, patients using psychotropics at baseline were at increased risk for intracranial bleeding.
Department of Haematology and Bone Marrow Transplantation Rambam Health Care Campus Haifa Israel
Department of Internal Medicine Hospital Sierrallana Santander Spain
Department of Internal Medicine Hospital Universitario de Puerto Real Cádiz Spain
Department of Internal Medicine Hospital Universitario Infanta Sofía Madrid Spain
Department of Pneumonology Hospital General Universitario de Alicante ISABIAL Alicante Spain
Department of Vascular Medicine Hôpital de Rangueil Toulouse France
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028343
- 003
- CZ-PrNML
- 005
- 20210114153558.0
- 007
- ta
- 008
- 210105s2020 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1055/s-0040-1708482 $2 doi
- 035 __
- $a (PubMed)32289861
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Marchena, Pablo Javier $u Department of Internal Medicine and Emergency, Parc Sanitari Sant Joan de Déu-Hospital General, Barcelona, Spain.
- 245 10
- $a Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism / $c PJ. Marchena, I. Tzoran, B. Brenner, M. Martín, R. Malý, A. Bura-Riviere, R. Valle, L. Hernández-Blasco, JB. López-Sáez, M. Monreal, RIETE Investigators,
- 520 9_
- $a BACKGROUND: The influence (if any) of the use of psychotropic drugs on outcome in patients receiving anticoagulant therapy for venous thromboembolism (VTE) has not been consistently evaluated. METHODS: We used data from the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the risk for VTE recurrences, major bleeding, or death during the course of anticoagulant therapy, according to the use of psychotropics at baseline. RESULTS: Among 49,007 patients with VTE enrolled from February 2009 to September 2019, total 5,230 (11%) were using psychotropics at baseline: antidepressants 3,273 (6.7%), antipsychotics 1,588 (3.2%), and anticholinesterases 369 (0.7%). During the course of anticoagulation, 1,259 patients developed VTE recurrences, 1,231 bled, and 3,988 died (fatal pulmonary embolism 269 and fatal bleeding 187). On multivariable analysis, patients using psychotropics at baseline had a similar risk for VTE recurrences (adjusted hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.58-1.12), a nonsignificantly higher risk for major bleeding (adjusted HR: 1.15; 95% CI: 0.97-1.35), and a higher risk for intracranial bleeding (adjusted HR: 1.83; 95% CI: 1.32-2.53) or death (adjusted HR: 1.44; 95% CI: 1.32-1.57) compared with those not using psychotropics. When separately analyzed, the highest risk for intracranial bleeding was found in patients using antidepressants (adjusted HR: 1.60; 95% CI: 1.08-2.37) or antipsychotics (adjusted HR: 2.02; 95% CI: 1.17-3.49) but not in those on anticholinesterases (adjusted HR: 1.69; 95% CI: 0.62-4.60). CONCLUSION: During the course anticoagulation for VTE, patients using psychotropics at baseline were at increased risk for intracranial bleeding.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antikoagulancia $x terapeutické užití $7 D000925
- 650 _2
- $a databáze faktografické $7 D016208
- 650 12
- $a lékové interakce $7 D004347
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a krvácení $x farmakoterapie $x epidemiologie $7 D006470
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a psychotropní léky $x terapeutické užití $7 D011619
- 650 _2
- $a riziko $7 D012306
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a žilní tromboembolie $x farmakoterapie $x epidemiologie $7 D054556
- 651 _2
- $a Španělsko $x epidemiologie $7 D013030
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Tzoran, Inna $u Department of Haematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
- 700 1_
- $a Brenner, Benjamin $u Department of Haematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
- 700 1_
- $a Martín, Mar $u Department of Internal Medicine, Hospital Universitario Infanta Sofía, Madrid, Spain.
- 700 1_
- $a Malý, Radovan $u Department of Cardiovascular Medicine I, Charles University in Prague, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Czech Republic.
- 700 1_
- $a Bura-Riviere, Alessandra $u Department of Vascular Medicine, Hôpital de Rangueil, Toulouse, France.
- 700 1_
- $a Valle, Reina $u Department of Internal Medicine, Hospital Sierrallana, Santander, Spain.
- 700 1_
- $a Hernández-Blasco, Luis $u Department of Pneumonology, Hospital General Universitario de Alicante, ISABIAL, Alicante, Spain.
- 700 1_
- $a López-Sáez, Juan Bosco $u Department of Internal Medicine, Hospital Universitario de Puerto Real, Cádiz, Spain.
- 700 1_
- $a Monreal, Manuel $u Department of Internal Medicine, Hospital Germans Trias i Pujol, Universidad Autónoma de Barcelona, Badalona, Barcelona, Spain.
- 710 2_
- $a RIETE Investigators
- 773 0_
- $w MED00004517 $t Thrombosis and haemostasis $x 2567-689X $g Roč. 120, č. 4 (2020), s. 620-626
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32289861 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114153555 $b ABA008
- 999 __
- $a ok $b bmc $g 1608678 $s 1119523
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 120 $c 4 $d 620-626 $e 20200414 $i 2567-689X $m Thrombosis and haemostasis $n Thromb Haemost $x MED00004517
- LZP __
- $a Pubmed-20210105
